Lantheus Holdings

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and Puerto Rico, third-party distribution in Europe, Canada, Australia, Asia-Pacific, and Latin America, and the EXINI business in Sweden. The company was founded in 1956 and is headquartered in North Billerica, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lantheus reports record revenues in 2022, eyes sustained growth

Lantheus' strong financial performance and market leadership position it well for continued growth.
While facing competition and investment challenges, Lantheus is focused on innovation and market expansion.
The company's strategic acquisitions, pipeline expansion, and guidance for 2023 signal a positive outlook.
Lantheus aims to maintain profitability while investing in key areas for future growth and market leadership.

Lantheus Holdings reports record Q1 results and eyes oncology growth

Lantheus Holdings delivered robust Q1 results driven by key products, with strong revenue and margin performance.
The company's strategic acquisitions and pipeline advancements position them well for future growth in oncology and Alzheimer's diagnostics.
While facing challenges with certain programs and undisclosed cancer types, Lantheus has outlined clear opportunities for market expansion and new treatment avenues.

Lantheus Holdings excels in Q2, eyes European expansion and innovation

Lantheus Holdings delivered robust Q2 2023 results, showcasing strong revenue growth and operational impact, with raised guidance reflecting confidence in sustained performance.
The company's focus on differentiation, market leadership, and strategic partnerships positions it well for growth despite competitive and regulatory challenges.
Opportunities in expanding market reach, diversification through radiotherapeutic candidates, and product innovation present avenues for future growth and market dominance.
Navigating challenges in competition, regulatory changes, and supply chain optimization will be crucial for Lantheus to maintain its market-leading position and drive continued success.

Lantheus Holdings excels in Q3 with strong revenue growth and market leadership

Lantheus Holdings' strong Q3 performance, driven by robust revenue growth and strategic advancements, positions the company well for future success. Despite challenges such as fixed costs and seasonal fluctuations, Lantheus remains focused on leveraging opportunities in the growing radiopharmaceutical market. With a leading market share, innovative pipeline, and solid financial position, Lantheus is poised for continued growth and value creation.

Lantheus Holdings achieves record revenues, eyes growth in radiopharmaceuticals

Lantheus Holdings delivered strong financial performance in 2023 with record revenues and growth.
The company is strategically positioned to capitalize on opportunities in radiopharmaceuticals and oncology.
Challenges include managing potential product transitions and maintaining market leadership.
Overall, Lantheus shows promise for continued growth and innovation in the healthcare sector.

Lantheus Holdings excels in Q1 2024, eyes $1B sales

Lantheus Holdings delivered a strong performance in Q1 2024, driven by robust sales of PYLARIFY and operational excellence, showcasing financial strength and profitability.
The company's focus on innovation, strategic partnerships, and pipeline opportunities positions it well for future growth and market leadership in radioligand therapy.
While facing challenges in a competitive landscape and evolving industry dynamics, Lantheus has opportunities for revenue growth, market expansion, and strategic collaborations to drive long-term success.

Lantheus Holdings excels in Q2 with strong sales and strategic acquisitions

Lantheus Holdings delivered strong financial performance in Q2 2024, driven by PYLARIFY's robust sales and strategic acquisitions strengthening their pipeline.
Despite facing challenges such as regulatory uncertainties and market competition, Lantheus remains well-positioned for growth and market leadership.
With a focus on innovation, market leadership, and strategic acquisitions, Lantheus is poised to capitalize on opportunities in the radiopharmaceutical market and drive sustained growth.

Lantheus Holdings reports robust Q3 performance amidst market opportunities

Lantheus Holdings (LNTH) delivered a strong performance in Q3 2024, driven by key products and revenue growth.
The company faces challenges in navigating market uncertainties and maintaining growth momentum.
Opportunities lie in expanding market presence, capitalizing on reimbursement changes, and advancing Alzheimer's diagnostics.
Overall, Lantheus Holdings shows promise for future growth and innovation in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA.

Full year 2023 worldwide revenue expected to be in the range of $1.295 – 1.297 billion, a 38 - 39% increase over the prior year including a $15 million RELISTOR milestone achievement

Lantheus Reports Preliminary Fiscal Year 2023 Revenue

BEDFORD, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Mary Anne Heino, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference at 11:15 a.m. PST on Wednesday, January 10.

Lantheus to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Cerence

UiPath

Undoubtedly, 2023 was the year of AI on Wall Street. We saw many AI-related companies absolutely skyrocket last year, with semiconductor firms leading the charge.

New Year, New Gains: The 3 Best AI Stocks to Buy in 2024

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Is It Worth Investing in Lantheus Holdings (LNTH) Based on Wall Street's Bullish Views?

Lantheus Holdings (LNTH) reachead $62 at the closing of the latest trading day, reflecting a -0.46% change compared to its last close.

Lantheus Holdings (LNTH) Declines More Than Market: Some Information for Investors

Allegro MicroSystems

Calix

Celsius Holdings

Civitas Resources

Darling Ingredients

Frontier Communications Corporation

HealthEquity

Interactive Brokers

Iridium Communications

Jazz Pharmaceuticals

MP Materials

Matador Resources

Perrigo

R1 RCM Inc

Teradata

TKO Group Holdings Inc

United Therapeutics

Valaris Ltd

Essential Utilities

When investors think about whether to increase their exposure beyond the big companies that grab most of the headlines in the financial media, they are likely to look at small-cap stocks first. After all, the sky's the limit.

20 midcap stocks with 2024 upside ranging up to 62%, according to analysts

Point Biopharma and Lantheus Holdings released positive topline results for their radioligand therapy in patients with metastatic castration-resistant prostate cancer. The SPLASH trial met its primary endpoint, showing a progression-free survival benefit compared to the control group. Both companies experienced a drop in stock prices despite the positive results, but the author remains bullish on Lantheus.

Lantheus Stock: Looking To Add After SPLASH's Belly-Flop

Point Biopharma Global

Shares of Lantheus Holdings Inc. LNTH, -2.38% and Point Biopharma Global Inc. PNT, +2.26% fell sharply premarket on Monday after the companies released new data from a trial of their experimental treatment for prostate cancer. The therapy, Lu-PNT2002, met the trial's primary goal, with a median progression-free survival of 9.5 months, compared with six months for patients on an alternative treatment, an androgen receptor pathway inhibitor, the companies said in a release.

Lantheus and Point Biopharma shares drop on prostate cancer treatment data

After reaching an important support level, Lantheus Holdings (LNTH) could be a good stock pick from a technical perspective. LNTH surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.

Lantheus Holdings (LNTH) Crossed Above the 200-Day Moving Average: What That Means for Investors

Lantheus Holdings (LNTH) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, LNTH crossed above the 20-day moving average, suggesting a short-term bullish trend.

Lantheus Holdings (LNTH) Recently Broke Out Above the 20-Day Moving Average

BEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes,, today announced Paul Blanchfield, President, and Bob Marshall, Chief Financial Officer and Treasurer, will present at the Jefferies London Healthcare Conference at 8:00 a.m. GMT (3 a.m. EST) on Wednesday, November 15.

Lantheus to Present at the Jefferies London Healthcare Conference

Lantheus Holdings, Inc. (NASDAQ:LNTH ) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Mark Kinarney - Vice President of Investor Relations Mary Anne Heino - Chief Executive Officer Paul Blanchfield - President Bob Marshall - Chief Financial Officer Conference Call Participants Roanna Ruiz - Leerink Richard Newitter - Truist Securities Matt Taylor - Jefferies Anthony Petrone - Mizuho Group Andy Hsieh - William Blair Justin Walsh - JonesTrading Larry Solow - CJS Securities Yuan Zhi - B. Riley David Turkaly - JMP Securities Operator Good morning.

Lantheus Holdings, Inc. (LNTH) Q3 2023 Earnings Call Transcript

Although the revenue and EPS for Lantheus Holdings (LNTH) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Lantheus Holdings (LNTH) Q3 Earnings: A Look at Key Metrics

BEDFORD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its third quarter ended September 30, 2023.

Lantheus Reports Third Quarter 2023 Financial Results

Disney

MercadoLibre

NextEra Energy

Pfizer

StoneCo

Atlassian

Risk and reward have an inverse relationship. It's one of the guiding principles of investing in stocks and any other asset.

7 Low-Risk Stock Picks to Double Your Money

Lantheus Holdings (LNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lantheus Holdings (LNTH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Is Lantheus Holdings (LNTH) a Buy as Wall Street Analysts Look Optimistic?

BEDFORD, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) --  Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 2, 2023, to discuss its financial and operating results for the third quarter of 2023.

Lantheus to Host Third Quarter 2023 Earnings Conference Call and Webcast on November 2, 2023, at 8:00 a.m. Eastern Time

Axcelis Technologies

Compass Minerals

Option Care Health

Super Micro Computer

Simpson Manufacturing

Weatherford International PLC

Right now, investors would be wise to consider the small-cap stocks that populate the Russell 2000 Index. The Russell 2000 Index represents the smallest firms by market capitalization.

7 Small-Cap Stocks to Buy Before the Next Recession Hits

Lantheus Holdings' stock price has increased more than 1000% since its IPO in 2015, with most gains occurring since 2022. The success of its product PYLARIFY, a PSMA-targeted PET imaging agent for prostate cancer, has driven significant revenue growth. Lantheus acquired rights to two radioligand drug candidates from Point Biopharma in 2022, targeting prostate cancer and neuroendocrine tumors.

Lantheus: Fast-Growing Radiotherapeutics Specialist Can Benefit From Lilly's POINT Biopharma Takeover

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Brokers Suggest Investing in Lantheus Holdings (LNTH): Read This Before Placing a Bet

Morningstar

Trupanion

If you're putting together a list of overlooked AI stocks, I wouldn't try to sneak Nvidia (NASDAQ: NVDA ) on it. Even investor neophytes know about CEO Jensen Huang's obsession with artificial intelligence ( AI ) and generative AI at the enterprise level.

3 Stealth AI Stocks That Everyone Is Overlooking

Wall Street Bulls Look Optimistic About Lantheus Holdings (LNTH): Should You Buy?

Terran Orbital Corp

Artificial intelligence is still all the rage with investors, but the hype has pushed many stocks to unsustainable heights. Now that the irrational frenzy is cooling off, some compelling opportunities are emerging away from the hot spotlight.

3 AI Stocks That Should Be on Every Investor's Radar This Fall

Lantheus Holdings (LNTH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

News for Lantheus Holdings Stock (LNTH)